Dow Jones
38.571,03 -115,29 (-0,30%) Nasdaq
16.828,67 +93,65 (+0,56%) Nikkei 225
38.923,03 +435,13 (+1,13%) EUR/USD
1,0911 +0,0005 (+0,04%) Bitcoin EUR
63.202,55 +984,93 (+1,58%) CMC Crypto 200
1.447,21 -20,72 (-1,41%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
Dopo ore:
| Chiusura precedente | 2,6400 |
| Aperto | 2,5400 |
| Denaro | 2,1000 x 100 |
| Domanda | 2,1900 x 100 |
| Min-Max giorno | 2,1000 - 2,5699 |
| Intervallo di 52 settimane | 1,3000 - 13,2000 |
| Volume | |
| Media Volume | 840.888 |
| Capitalizzazione | 3,102M |
| Beta (mensile su 5 anni) | 0,55 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -21,8500 |
| Prossima data utili | 07 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,00 |
GlobeNewswireCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:
